Table 1.
Baseline characteristics by treatment group and for the total sample
| Characteristic | PEG 2a + RV (n = 55) |
PEG 2a + PL (n = 59) |
Total Sample (N = 114) |
|
|---|---|---|---|---|
| Age, yrs | 10.7 ± 3.3 | 10.8 ± 3.6 | 10.7 ± 3.4 | |
| 5 - 11 | 30 (54%) | 30 (51%) | 60 (53%) | |
| 12 - 18 | 25 (46%) | 29 (49%) | 54 (47%) | |
| Gender | Male | 27 (49%) | 36 (61%) | 63 (55%) |
| Female | 28 (51%) | 23 (39%) | 51 (45%) | |
| Race | White | 43 (78%) | 42 (71%) | 85 (75%) |
| Black / African American | 1 (2%) | 4 (7%) | 5 (4%) | |
| Asian | 3 (6%) | 2 (3%) | 5 (4%) | |
| American Indian / Alaska Native | 1 (2%) | 0 (0%) | 1 (1%) | |
| More than one race | 1 (2%) | 5 (9%) | 6 (5%) | |
| Unknown | 6 (11%) | 6 (10%) | 12 (11%) | |
| HCV genotype | 1 | 45 (82%) | 47 (80%) | 92 (81%) |
| 2 | 4 (7%) | 3 (5%) | 7 (6%) | |
| 3 | 6 (11%) | 7 (12%) | 13 (11%) | |
| 6 | 0 (0%) | 2 (3%) | 2 (2%) | |
| Transmission mode | Maternal-infant | 39 (71%) | 47 (80%) | 86 (75%) |
| Transfusion | 6 (11%) | 2 (3%) | 8 (7%) | |
| Other | 10 (19%) | 10 (18%) | 20 (18%) | |
| Estimated duration of infection, mos. | 105 ± 56 | 111 ± 55 | 108 ± 55 | |
| ALT (IU/L) | 49 ± 59 | 49 ± 59 | 49 ± 59 |
Note: Treatment groups did not differ significantly on any characteristic (all p-values > 0.05).